Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stock Report

Market Cap: US$58.5b

Alnylam Pharmaceuticals Valuation

Is ALNY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALNY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$377.92
Fair Value
18.3% overvalued intrinsic discount
28
Number of Analysts

Below Fair Value: ALNY ($447) is trading above our estimate of fair value ($377.92)

Significantly Below Fair Value: ALNY is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALNY?

Key metric: As ALNY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALNY. This is calculated by dividing ALNY's market cap by their current revenue.
What is ALNY's PS Ratio?
PS Ratio23.8x
SalesUS$2.46b
Market CapUS$58.53b

Price to Sales Ratio vs Peers

How does ALNY's PS Ratio compare to its peers?

The above table shows the PS ratio for ALNY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.3x
REGN Regeneron Pharmaceuticals
4.2x6.02%US$60.2b
ONC BeOne Medicines
8x14.45%US$33.7b
NTRA Natera
11.8x13.25%US$23.1b
VRTX Vertex Pharmaceuticals
9x9.31%US$100.3b
ALNY Alnylam Pharmaceuticals
23.8x25.79%US$58.5b

Price-To-Sales vs Peers: ALNY is expensive based on its Price-To-Sales Ratio (23.8x) compared to the peer average (8.3x).

Price to Sales Ratio vs Industry

How does ALNY's PS Ratio compare vs other companies in the US Biotechs Industry?

135 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2x-1.06%US$19.39b
INCY Incyte
3.7x1.87%US$16.52b
BMRN BioMarin Pharmaceutical
3.7x6.70%US$11.19b
MRNA Moderna
3.1x19.70%US$9.37b
ALNY 23.8xIndustry Avg. 8.7xNo. of Companies135PS01632486480+
135 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALNY is expensive based on its Price-To-Sales Ratio (23.8x) compared to the US Biotechs industry average (8.7x).

Price to Sales Ratio vs Fair Ratio

What is ALNY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALNY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.8x
Fair PS Ratio17.4x

Price-To-Sales vs Fair Ratio: ALNY is expensive based on its Price-To-Sales Ratio (23.8x) compared to the estimated Fair Price-To-Sales Ratio (17.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALNY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$447.00
US$426.26
-4.64%
19.80%US$583.00US$236.00n/a28
Aug ’26US$401.80
US$417.58
+3.93%
18.31%US$550.00US$236.00n/a30
Jul ’26US$322.06
US$325.06
+0.93%
18.08%US$500.00US$212.00n/a31
Jun ’26US$304.56
US$320.62
+5.27%
16.86%US$500.00US$212.00n/a31
May ’26US$255.13
US$317.30
+24.37%
17.26%US$500.00US$212.00n/a31
Apr ’26US$255.76
US$314.17
+22.84%
18.32%US$500.00US$206.00n/a31
Mar ’26US$246.75
US$304.61
+23.45%
19.12%US$500.00US$195.00n/a30
Feb ’26US$271.31
US$299.74
+10.48%
16.57%US$400.00US$200.00n/a30
Jan ’26US$235.31
US$299.11
+27.11%
17.14%US$400.00US$178.00n/a30
Dec ’25US$253.07
US$298.77
+18.06%
17.16%US$400.00US$178.00n/a30
Nov ’25US$273.91
US$301.32
+10.01%
16.68%US$400.00US$180.00n/a29
Oct ’25US$276.06
US$285.91
+3.57%
19.63%US$400.00US$160.50n/a28
Sep ’25US$262.69
US$282.72
+7.63%
19.50%US$400.00US$160.50US$446.5127
Aug ’25US$268.61
US$269.76
+0.43%
19.47%US$400.00US$160.50US$401.8027
Jul ’25US$243.32
US$248.46
+2.11%
21.86%US$400.00US$150.00US$322.0627
Jun ’25US$148.43
US$220.38
+48.48%
23.05%US$400.00US$138.00US$304.5626
May ’25US$149.96
US$219.85
+46.61%
23.14%US$395.00US$136.00US$255.1327
Apr ’25US$153.33
US$220.62
+43.88%
23.29%US$395.00US$136.00US$255.7626
Mar ’25US$152.61
US$219.65
+43.93%
22.94%US$395.00US$136.00US$246.7526
Feb ’25US$174.92
US$226.12
+29.27%
20.71%US$395.00US$144.00US$271.3126
Jan ’25US$191.41
US$224.46
+17.27%
21.61%US$395.00US$135.00US$235.3126
Dec ’24US$171.41
US$224.08
+30.73%
21.56%US$395.00US$135.00US$253.0726
Nov ’24US$157.00
US$225.41
+43.57%
21.83%US$395.00US$125.00US$273.9126
Oct ’24US$177.10
US$243.63
+37.57%
18.94%US$405.00US$134.00US$276.0626
Sep ’24US$201.17
US$244.07
+21.32%
18.90%US$405.00US$141.00US$262.6925
AnalystConsensusTarget
Consensus Narrative from 28 Analysts
US$426.26
Fair Value
4.9% overvalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/02 18:52
End of Day Share Price 2025/08/29 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 67 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg